Elevance Health, Inc. — Form 8-K
Filed July 15, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 52/100
What the filing says
Elevance Health reported Q2 2026 operating revenue of $49.8B (up 0.8% YoY) with diluted EPS of $6.71 and adjusted EPS of $7.45. The company raised FY2026 diluted EPS guidance to at least $20.10 and adjusted EPS to at least $27.00, and raised operating cash flow guidance to at least $6.0B. However, the filing discloses a $935M accrual ($4.27/share) for potential Medicare Advantage risk adjustment exposure related to a February 27, 2026 CMS notice regarding historical data issues. Medical membership declined 469K sequentially to 44.9M; operating margins compressed 140 basis points YoY to 3.5% due to elevated medical costs and workforce investments.
Why this rating
Guidance raise is offset by $935M regulatory accrual (~1.1% of company size). Membership declines and margin compression are concerning; moderate negative event relative to $87.3B market cap.
See more from July 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.